BRIM Biotechnology Inc Sustainability Reports

BRIM Biotechnology Inc. is a Taiwan-based clinical-stage biopharmaceutical company focused on innovative drug discovery and development. The company leverages its proprietary Pigment Epithelium-Derived Factor (PEDF) short-chain peptide technology platform to develop therapeutics for ophthalmic diseases and degenerative arthritis.

Sector: Manufacturing

Country: Taiwan

Exchange: Taiwan Stock Exchange

FIGI: BBG00BR8KDV3

10 reports from 2021 to 2025

• BRIM Biotechnology Inc 2025 Annual Report
• BRIM Biotechnology Inc 2024 Sustainability Report
• BRIM Biotechnology Inc 2024 Financial Report and Independent Auditors' Report
• BRIM Biotechnology Inc 2024 Sustainability Report
• BRIM Biotechnology Inc 2024 Annual Report